Toxoplasmic encephalitis in a non-HIV patient with follicular lymphoma.
Touahri
Tahar
T
Pulik
Marc
M
Fezoui
Hacene
H
Genet
Philippe
P
Lionnet
François
F
Louvel
Delphine
D
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D016898:Interferon-alpha / Q000008:administration & dosage; D008224:Lymphoma, Follicular / Q000150:complications*; D009894:Opportunistic Infections / Q000209:etiology*; D011241:Prednisone / Q000008:administration & dosage; D016879:Salvage Therapy; D013713:Teniposide / Q000008:administration & dosage; D016781:Toxoplasmosis, Cerebral / Q000150:complications*; D014740:Vidarabine / Q000009:adverse effects* / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D016898:Interferon-alpha; D003561:Cytarabine; D005047:Etoposide; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D013713:Teniposide; D014740:Vidarabine; C024352:fludarabine; D002945:Cisplatin; D011241:Prednisone